Flow Cytometric Enumeration of Peripheral Blood CD34 Cells Predicts Bone Marrow Pathology in Patients with Less Than 1% Blasts by Manual Count.

Background And Aims: Significance of absolute number of CD34 cells in the peripheral blood of patients with less than 1% myeloblasts by manual differential count is unknown and our aim is to study its relevance in clinical practice.

Methods: We studied 138 peripheral bloods flow cytometric analyses in patients with less than 1% myeloblasts by manual differential, when CD34 events were present in the gate that encompassed lymphocytes, monocytes, stem cells, and blasts.

Results: The average absolute number of CD34cells in the peripheral blood was 11 CD34cells/µL ranging from less than 1 cell/µL to 147 cells/µL.

Atypical Localization of Malignant Plasma Cells in Non-Viable Cell Area on Flow Cytometry Light-Scatter Dot Plot.

BACKGROUND Multi-parameter (multicolor) flow cytometric study of the bone marrow aspirate is a very useful tool for diagnosis of plasma cell dyscrasia and for evaluation of post-therapy bone marrow for minimal residual disease. CASE REPORT We present a case of a 50-year-old man with multiple myeloma, whose plasma cells on a bone marrow aspirate flow cytometric study showed atypical placement on a light-scatter dot plot, both on forward and side scatter. The bone marrow aspirate sample was 33 hours and 11 minutes old, and the light-scatter dot plot demonstrated that plasma cells, detected by their expression of CD138, CD38, and CD56, occupied an area otherwise characteristic for dead cells and cell detritus.

Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.

Administration of adenovirus (Ad) vectors to animals induces innate immune responses, typified by elevated interleukin-6 (IL-6). To assess innate responses to Ad vectors in humans, we evaluated serum IL-6 following administration of E1(-) E3(-) Ad vectors to different human hosts and the relationship among peak IL-6 and peak anti-Ad neutralizing antibodies. We administered: 1) Ad(GV)CFTR.